ResearcherThe University of TokyoNo recent work listed
Yasuhiro Hagiwara
Matched on ORCID iD 0000-0003-3792-5368; OpenAlex author ID A5027529203. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 36
2017: 2 papers · 2018: 1 paper
Papers 3
- Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… Co-author DOI 10.1016/j.ejca.2018.01.081↗
- Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
Closest collaborators
The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yasuo Ohashi · 3 shared papers, 2017–2018 · strength 0.17
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone… DOI 10.1136/esmoopen-2016-000151↗
- Paper Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily reg… DOI 10.1007/s00280-017-3250-8↗
- Narikazu Boku · 2 shared papers, 2017–2018 · strength 0.12
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone… DOI 10.1136/esmoopen-2016-000151↗
- Shoji Nakamori · 2 shared papers, 2017–2018 · strength 0.11
- Paper Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Res… DOI 10.1016/j.ejca.2018.01.081↗
- Paper Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily reg… DOI 10.1007/s00280-017-3250-8↗
- Shinichi Ohkawa · 2 shared papers, 2017 · strength 0.11
- Paper Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone… DOI 10.1136/esmoopen-2016-000151↗
- Paper Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily reg… DOI 10.1007/s00280-017-3250-8↗
- Hideki Ueno · 2 shared papers, 2017 · strength 0.11
- Paper Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone… DOI 10.1136/esmoopen-2016-000151↗
- Paper Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily reg… DOI 10.1007/s00280-017-3250-8↗
- Akira Fukutomi · 1 shared paper, 2018 · strength 0.06
- Takeshi Sudo · 1 shared paper, 2018 · strength 0.06
- Yuji Kaneoka · 1 shared paper, 2018 · strength 0.06
- Koji Imai · 1 shared paper, 2018 · strength 0.06
- Naohiro Sata · 1 shared paper, 2018 · strength 0.06
- Katsuhiko Uesaka · 1 shared paper, 2018 · strength 0.06
- Yukiyasu Okamura · 1 shared paper, 2018 · strength 0.06
- Ippei Matsumoto · 1 shared paper, 2018 · strength 0.06
- Soichiro Morinaga · 1 shared paper, 2018 · strength 0.06
- Satoshi Hirano · 1 shared paper, 2018 · strength 0.06
- Taketo Yamaguchi · 1 shared paper, 2017 · strength 0.05
- Atsushi Satō · 1 shared paper, 2017 · strength 0.05
- Takashi Hatori · 1 shared paper, 2017 · strength 0.05
- Tatsuya Ioka · 1 shared paper, 2017 · strength 0.05
- Shinichi Egawa · 1 shared paper, 2017 · strength 0.05
- Ann‐Lii Cheng · 1 shared paper, 2017 · strength 0.05
- Akihiro Funakoshi · 1 shared paper, 2017 · strength 0.05
- Junji Furuse · 1 shared paper, 2017 · strength 0.05
- Masao Tanaka · 1 shared paper, 2017 · strength 0.05
- Takuji Okusaka · 1 shared paper, 2017 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.